Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellectricon Announces Project Grant Winners

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
The grant was awarded for project proposals utilizing Cellectricon’s Cellaxess ACE technology for the delivery of non-genetic material to adherent cells and cultures.

Cellectricon has announced the two winners of its Cellaxess® ACE project grant, supporting cutting-edge research in cell biology. The winners not only receive a Cellaxess ACE module and consumables, but will also benefit from Cellectricon’s on-going support and expertise throughout the project’s duration. Cellaxess ACE is a single electrode based electroporation system optimized for the in-situ transfection of all adherent cell types, which offers superior efficiency and cell viability due to minimal cell processing and the low voltages required.

The awards were granted for two categories: Applied Cell-Based Research and Basic Cell-Based Research. Dr Hakim Djaballah, Director of the HTS Core Facility, Memorial Sloan-Kettering Cancer Centre, New York, received the award for Applied Research. His project looks at small molecule delivery in 3D cell models using electroporation, benefiting from Cellectricon’s Cellaxess ACE technology to push the limits of compound delivery to all cells of a 3D spheroid, not just those at the periphery. In such a fast-paced research area, compound uptake in a 3D system has major implications for translational medicine. 

Exploring the intracellular delivery of Ca2+ channel peptides using the Cellaxess ACE, Dr Gary Stephens, Director of Pharmacology at the University of Reading School of Pharmacy, received the award for Basic Cell-based Research. The group has recently developed synthetic peptides for decreasing the Ca2+ influx into neurons, which therefore modulates synaptic transmission. Using the Cellaxess ACE to deliver these peptides will be instrumental in examining their modulatory effects in adherent neurons, potentially leading to therapeutic agents in areas such as pharmacoresistant pain. 

Dr Johan Pihl, Product Manager for the Cellaxess ACE, comments: “We were delighted with the response to our Cellaxess Project Grant – with so many highly qualified applications, choosing the winning abstracts was a tough decision. It’s going to be exciting to see how our Cellaxess technology enhances this cutting-edge research.” 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellectricon Establishes Scientific Advisory Board to Enhance Its Pain and CNS Discovery Services
The company, a leading provider of advanced cell-based discovery services, has appointed Dr Edwin Johnson, Director of The Stockholm Brain Institute, as the first member of its new Scientific Advisory Board.
Thursday, July 09, 2015
UCL’s Novel Approach to Research in Biologically-Relevant Models
Cellectricon and UCL unite to present a webinar, March 27, 11am-12pm EDT.
Wednesday, March 19, 2014
Presenting Phenotypic Screening Strategies for Chronic Pain Research
Cellectricon explores novel phenotypic assay designs in a webinar, 5 September, 11am-12pm (EDT).
Wednesday, August 21, 2013
Cellectricon Launches Grant to Fund Electroporation-based Research
New Cellaxess® Project Grant supports advanced research projects.
Wednesday, July 10, 2013
Identifying Unknown Modulators of Pain with New Phenotypic Assays
Cellectricon presentation: SMi Pain Therapeutics conference, 20 May, 11am.
Tuesday, May 14, 2013
Dr. Paul Karila appointed Head of Discovery Services at Cellectricon AB
Discovery services will be based on automated cellular electric field manipulation for novel screening applications.
Wednesday, June 13, 2012
Cellectricon Receives Milestone Order for Cellaxess®HT High Throughput RNAi Screening System
Cellectricon receives the largest single order to deliver three Cellaxess®HT systems to a leading US biotech firm.
Friday, November 14, 2008
Scientific News
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Process Contaminants in Vegetable Oils and Foods
Glycerol-based process contaminants found in palm oil, but also in other vegetable oils, margarines and some processed foods, raise potential health concerns for average consumers of these foods in all young age groups, and for high consumers in all age groups.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!